Logo
x

Search

Subscribe Now

bio-thera

Bio-Thera Reports the EMA’s Approval of Avzivi (Biosimilar, Avastin) for Treating Multiple Indications

Bio-Thera Reports the EMA’s Approval of Avzivi (Biosimilar, Avastin) for Treating Multiple Indications

  • July 30, 2024
Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU

Bio-Thera Reports the Regulatory Filing Acceptance for BAT2206 (Biosimilar, Stelara) Across the US and EU

  • July 24, 2024
Bio-Thera Gains the CHMP’s Positive Opinion of Avzivi (Biosimilar, Avastin)

Bio-Thera Gains the CHMP’s Positive Opinion of Avzivi (Biosimilar, Avastin)

  • June 3, 2024
Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi)

Bio-Thera Collaborates with STADA for the Commercialization of BAT2506 (Biosimilar, Simponi)

  • May 29, 2024
Bio-Thera Reports the US FDA’s Approval of Avzivi (Biosimilar, Avastin)

Bio-Thera Reports the US FDA’s Approval of Avzivi (Biosimilar, Avastin)

  • December 8, 2023
Bio-Thera Reports the Results for BAT2206 in P-III Trial for the Treatment of Plaque Psoriasis

Bio-Thera Reports the Results for BAT2206 in P-III Trial for the Treatment of Plaque Psoriasis

  • December 6, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.